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ABSTRACT

THE DEVELOPMENTAL IMPLICATIONS OF THE REGULATORY
RELATIONSHIP BETWEEN CJUN AND OCT4 IN MURINE EMBRYONIC STEM
CELLS

Rachel Brewer

As cells transition from the point of fertilization through the process of embryonic
development, many molecular changes occur that affect cell fate. At the blastocyst stage,
the earliest distinction, two separate cell populations arise. The trophectoderm cells will
generate all of the extraembryonic tissues while the inner cell mass will yield all of the
embryonic tissues. These cells, which generate the organism, are termed pluripotent at
this stage and found within the inner cell mass (ICM). A variety of genetic mechanisms
that regulate this event have been characterized. Here, we examined the effect of cJun
expression in regulating Oct4, a gene known to be a master regulator of pluripotency.
Luciferase assays were performed to validate our bioinformatics analysis of the 3 kb Oct4
promoter, which identified a cJun binding site approximately 2500 bp upstream of the
transcription start site. These experiments demonstrate transient expression of cJun off a
reporter plasmid significantly increases luciferase activity of the Oct4-luciferase reporter
construct, while expression of the transcriptionally inactive cJun mutant L40/42A
represses it. Additionally, we corroborate previous reports that cJun can synergize with
Beta-catenin, a member of the Wnt pathway, to significantly increase the promoter
activity of Oct4. A role for regulation of endogenous Oct4 expression was
ii

evaluated by immunoblot analysis of murine embryonic stem cells transiently transfected
with GFP cJun, which demonstrated increased OCT4A expression 36 hours posttransfection. To assess the developmental implications of this regulatory relationship, we
evaluated the effect of cJun overexpression on early differentiation by transiently
transfecting mESCs and initiating embryoid body formation. When evaluated for germ
layer marker expression by immunoblot analysis, it was revealed that an increase in cJun
correlated with an increase in GATA4 expression, suggesting cJun expression could lead
to selection toward the endodermal germ layer. In light of this, we carried out directed
differentiation into cardiomyocytes, using a hanging drop intermediate, and found that an
increase in cJun led to a significant increase in cardiomyocyte formation and beating.
Overall, this suggests a new role for cJun in the regulation of potency and the formation
of the endoderm during those early cell fate choices.
Key Words: pluripotent, cell fate, germ layer, cJun, Oct4
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INTRODUCTION

OCT4 as a Key Developmental Transcription Factor
OCT4 is a member of the POU transcription factor family homeodomain. It is
highly expressed during the early stages of mouse development and has been shown to be
essential in the formation of the pluripotent inner cell mass (ICM) (Scholer et al. 1990;
Nichols et al. 1998). Without Oct4, the cells of the ICM are unable to give rise to the
three germ layers, and are therefore developmentally restricted to yielding only the
trophectoderm (TE) lineage (Nichols et al. 1998; Velkey and O’Shea 2003). Induced
deletion of Oct4 in embryos as they transition from the morula to blastocyst stage causes
a deficiency in lineage determination; the cells of the ICM cannot differentiate toward
primitive endoderm and the embryo does not progress from blastocyst to epiblast (Le Bin
et al. 2014). Reduced OCT4 concentration in mESCs through heterozygosity maintains
pluripotency, but causes a delayed response to differentiation cues that ultimately affect
the critical timing of development (Karwacki-Neisius et al. 2013).
Previous work has established OCT4 as an essential regulatory protein that
determines lineage commitment (Niwa et al. 2000; Zeineddine et al. 2006; Rodriguez et
al. 2007; Le Bin et al. 2014). The transcription factor is expressed at levels comparable to
the ICM in migrating endoderm cells, which come into contact with the TE as they
differentiate during the blastocyst stage (Palmieri et al. 1994). A less than two-fold
increase in Oct4 expression can lead to mesoderm and primitive endoderm formation,
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while a less than two-fold decrease causes embryonic stem cell differentiation to TE,
suggesting that there is a critical, highly specific, level of Oct4 necessary to maintain
pluripotency; it’s not simply on or off when regulated (Niwa et al. 2000). Further
analyses revealed that increased Oct4 expression can result in the establishment of the
cardiac lineage population in both mESCs and embryos entering the early stages of
differentiation (Zeineddine et al. 2006; Rodriguez et al. 2007).
There is significant evidence that Oct4 is also critical to the regulation of later
stages of development. Boyer et al. (2005) discovered that a group of genes regulated by
OCT4, NANOG and SOX2 are key developmental players. RNAi studies have shown
that reduced expression of OCT4 and NANOG in mES cells affects the gene expression
of their targets, ultimately changing cell fate (Loh et al. 2006). OCT4 binds to lowaccessible genomic regions, activating enhancers that would otherwise remain
unresponsive to specific differentiation cues (Simandi et al. 2016). Frum et al. (2013)
found that OCT4 is required for NANOG mediated Fgf4/MAPK signaling as the
primitive endoderm (PrE) is specified, since exogenous treatment of Fgf4 was not
sufficient to induce expression of Sox17 and other PrE markers in Oct4 null E2.75-E4.5
mouse embryos. As cells are guided toward endoderm differentiation, OCT4 alternates
binding the enhancer regions of the Sox2/Sox17 loci between Sox2 and Sox17. This has
been shown to be an essential step in the formation of mesendoderm and mesoderm
(Aksoy et al. 2013; Abboud et al. 2015).
Coordinated regulation of Oct4 gene expression is critical to achieving proper
embryonic development. Therefore, a significant amount of work has been performed to
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better understand the regulation of Oct4 transcription and post-transcriptional mRNA
processing. Oct4 gene expression is conserved across many mammalian species. Gene
transcription is initiated by a GC-rich region of the TATA-less promoter (Reviewed in
Jerabek et al. 2014). Upstream of the transcription start site, the Oct4 promoter region
possesses two highly conserved enhancer elements which cumulatively span a region of
approximately 3,000 base pairs. The distal (-3.2 kb-1.39 kb) and proximal (-1.39 kp-0)
enhancers are both tissue-specific and developmentally restricted (Yeom et al. 1996;
Reviewed in Jerabek et al. 2014; Choi et al. 2016). The distal enhancer is the primary
source of regulation preimplantation (Choi et al. 2016). Upon implantation, the proximal
enhancer plays a key role in driving transcription within the epiblast and the distal
enhancer is restricted to the germ cell lineage (Reviewed in Jerabek et al. 2014). The
promoter/enhancer region of Oct4 is hypomethylated in the pluripotent cells of the ICM;
however, it is hypermethylated in the cells that ultimately give rise to the trophectoderm,
further highlighting the critical developmental timing of Oct4 expression (Hattori et al.
2004).
Many transcription factors have been shown to bind target sequences within the
Oct4 promoter. One of which is OCT4. OCT4 heterodimerizes with SOX2 and binds an
OCT-SOX regulatory element in the distal enhancer to increase transcription (Chew et al.
2005). Another transcription factor complex that binds Oct4 is LEF/TCF4. Three
LEF/TCF4 binding sites have been identified in the Oct4 promoter, one in the proximal
region (-881/875) and two in the distal (-1661/1665 and -2032/2026). Constitutively
active Beta-catenin can increase activity off of these sites, suggesting regulation of Oct4
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expression is one mechanism by which the Wnt signaling cascade regulates pluripotency
(Wei et al. 2012). As the developing embryo next exits gastrulation, the Oct4 gene is
directly bound by germ cell nuclear factor (GCNF) which leads to the subsequent
recruitment of a de novo methyltransferase; and ultimately, expression is silenced in all
cells except those of the germ line (Fuhrmann et al. 2001; Wang et al. 2016).
Alternative splicing and translation are other mechanisms used to regulate OCT4
activity. The murine Oct4 gene generates four isoforms: OCT4A 352aa, OCT4B-247aa,
OCT4B-190aa and OCT4B-164aa (Figure 1). The OCT4A isoform is the only one to
contain the first exon and therefore has an unique N-terminus. Additionally, this
alternative splicing leads to the exclusion of exon 2a, which becomes the distinct Nterminus of the OCT4B isoforms. As in humans, the OCT4A isoform is regarded as a
keeper of pluripotency. Until recently, the OCT4B isoforms remained elusive in function
and sequence. Of the identified OCT4B isoforms, OCT4B-247aa, containing the full
intact N-terminus, and OCT4B-164aa were localized in the nuclei of non-pluripotent cells
while OCT4B-190aa was mainly found in the cytoplasm, suggesting these different
isoforms may have different functions due to their subcellular localization (Guo et al.
2012). Furthermore, during somatic cell reprogramming, OCT4B isoforms were unable
to replace OCT4A thereby offering additional evidence that OCT4A, specifically, is
essential for pluripotency (Guo et al. 2012). Because many IRES containing mRNAs are
involved in stress response, Guo et al. (2012) examined the OCT4B isoforms under
hyperpyrexia and hyperxia conditions, in mES cells. Interestingly, they found that
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OCT4B-190aa, which was mainly found in the cytoplasm, was upregulated over time in
response to stress.
While there is still a great deal left unknown about the mouse Oct4 gene and the
variants it encodes, more information is emerging regarding the corresponding human
OCT4 isoforms. Analogously, the human OCT4 gene generates three known, stable
isoforms through alternative splicing or alternative translation: OCT4A, OCT4B and
OCT4B1. Over the last several years, the differential expression patterns of the various
isoforms have been studied more actively, noting that the OCT4A variant is highly
expressed, and restricted, to the nuclei of pluripotent human ES (hES) cells and
embryonal carcinoma (hEC) cells (Atlasi et al. 2008; Reviewed in Wang and Dai 2010).
OCT4A has been a known transcription factor and key regulator of pluripotency in stem
cells while OCT4B, which is typically located in the cytoplasm of non-pluripotent cell
types, has more recently been implicated in stress resistance (Atlasi et al. 2008; Wang et
al. 2009). OCT4B1, interestingly, has a nearly identical amino acid sequence (residues 180 are the same) compared with OCT4B, however it is highly expressed in pluripotent
hES and hEC cells and downregulated during differentiation (Atlasi et al. 2008). The
OCT4A variant has been shown to be essential in maintaining stemness during
embryogenesis while OCT4B, was proven insufficient for self-renewal and maintaining
pluripotency (Reviewed in Wang and Dai 2010). Taken together these data suggest that
the OCT4A isoform will play a much greater role in the development and differentiation
of an organism.
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Figure 1. Alternative Splicing and IRES in mouse Oct4 Gene Leads to Multiple
Isoforms
(top) The mouse Oct4 gene contains five exons and four introns following the
transcription start site (black arrow). Through alternative splicing, two different mRNA
transcripts are produced: Oct4A (left, middle) and Oct4B (right, middle). The Oct4A
transcript is unique in that it’s the only one that contains the first exon, which then
becomes the unique N-terminus of the subsequent OCT4A protein (left, bottom). The
Oct4B transcript contains an IRES which gives rise to three unique isoforms of varying
length (right, bottom) (Guo et al 2012).

The Regulatory Potential of cJun on Oct4
cJun is a transcription factor belonging to the AP-1 family. It is implicated in a
myriad of cellular processes including cellular division, cellular migration, and apoptosis
(Wilkinson et al. 1989; Eferl et al. 1999; Behrens et al. 2002). Its activity is regulated by
many processes including gene expression, alternative translation and post-translational
modifications. cJun has been shown to regulate its own transcription through a positive
feedback loop in response to specific stimuli (Angel et al. 1988) however, perhaps the
best characterized example of its regulation is post-translational: the direct
phosphorylation of cJun by c-Jun N-terminal kinases (JNKs). JNKs are a subfamily of
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mitogen-activated protein kinases (MAPKs) discovered by their ability to bind and
phosphorylate cJun. Active JNK binds c-Jun at leucines L40/42 to phosphorylate serines
63 and 73. Phosphorylation of these residues is necessary for transcriptional activity of
consensus AP-1 sites (Smeal et al. 1992; Czaja 2003; Sprowles and Wisdom 2003). If
phosphorylated cJun dimerizes with a dominant negative mutant, the DNA binding
activity may be reduced (Smeal et al. 1992).
cJun can also be regulated at the translational level. A cap-independent
translation mechanism for cJun was first proposed in chicken cells (Sehgal et al. 2000).
Others have now corroborated this report in various cell lines including HeLa, 293T,
NIH3T3 and patient derived glioblastoma cell lines (Polak et al. 2006; Blau et al. 2012).
They found that upon de-polymerization of actin filaments and microtubules, there was
an increase in cJun protein but not mRNA. Furthermore, the protein half-life was
comparable to the controls suggesting that the increase was not simply due to an
accumulation of protein over time. MAPKs, particularly JNKs, are activated in response
to cytoskeletal stress and are known to regulate cJun; however, increased translation via
the virus-like IRES domain in the 5’UTR (untranslated region) occurs independent of
MAPK activity (Polak et al. 2006; Spangler et al. 2010; Blau et al. 2012). Increased cJun
by cytoskeletal disruption has also been associated with increased malignant behaviors of
glioblastoma lines (Blau et al. 2012).
cJun plays a critical role not only in disease, but in embryonic development. A
null mutation in the cJun locus results in embryonic lethality at 11-12 days post coitus in
mice (Johnson et al. 1993). cJun-/- mice die during mid- to late-gestation and show
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impaired development of some endoderm-derived organs (Hilberg et al. 1993). The
ability to form fibroblasts with proper morphology and liver cells in culture were
adversely affected by the loss of cJun suggesting a greater role in specific cell types,
including those involved in cardiac formation (Johnson et al. 1993; Eferl et al. 1999).
cJun is also consistently expressed during neural development in normal embryogenesis
(Raivich and Behrens 2006). Exogenous cJun expression in p19 cells leads to endodermand mesoderm-like differentiation and has been shown to be essential for cardiomyocyte
differentiation (Groot et al. 1990; Eriksson and Leppa 2002).
More recently, the role for cJun in ICM potency and cell fate has been described
in murine embryonic stem cells. cJun forces mESCs out of the ground state of
pluripotency and on to a somatic fate with restricted proliferation (Liu et al. 2015). Cells
overexpressing cJun have increased mRNA of early developmental genes including
Gata4 and Sox17, while the expression of pluripotent genes, including Oct4, Nanog and
Sall4, critical to stem cell function, become inhibited (Liu et al. 2015). The work
performed by Liu et al. caused them to propose a model wherein cJun serves as a master
regulatory function to drive the differentiation of the inner cell mass within the
developmental context.
Our lab discovered a putative AP-1 binding site within the promoter region of the
murine Oct4 promoter (Figure 2). Furthermore, we have demonstrated that when cJun is
phosphorylated at S63, the OCT4A isoform is overexpressed in mESCs (Hosawi et al. in
prep). Transient expression of cJun constructs has demonstrated a decrease in
differentiation capacity of mESCs to pancreatic islet-like clusters (Hosawi et al. in prep).
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Taken together these data suggest that JNK signaling and cJun affect cell fate during
differentiation by altering the potency of mESCs (Hosawi et al. in prep). Based on our
work and that of Liu et al. (2015), we hypothesize these changes would be best
characterized as the ICM cells move out of pluripotency and into early germ layer
development.
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Figure 2. Identification of AP-1 Binding Sites in the Oct4 Promoter of Mus musculus
Utilizing the NCBI database (Accession number NT_039662), a putative AP-1 binding
site was found in the distal promoter of Oct4 approximately 3,000 base pairs (bp)
upstream of the transcription initiation site. Three TCF/LEF sites 2kb (not shown), 1.6kb
(not shown) and 800bp (shown at -888 bp to -882 bp) upstream of the initiation site have
been shown to regulate Oct4 expression by others (Li et al 2012). The location and
proximity of these two binding sites suggest they may be involved in transcriptional
regulation of the Oct4 gene.
Embryoid Bodies as a Model for Murine Development
Embryoid bodies (EBs) are one system used to study the cellular and genetic
changes that occur as mES cells exit the pluripotent state. These small, cellular structures
form due to spontaneous differentiation of mESCs when grown in suspension culture in
the absence of a feeder layer (Reviewed in Keller 1995). They have been used to study
the specific onset of developmental programming in human ES cells (Itskovitz-Eldor et
al. 2000) and mouse ES cells (Reviewed in Desbaillets et al. 2001). EBs offer an
advantage as a developmental model because they maintain the integrity of cell-cell
contacts, which may offer critical developmental cues (Reviewed in Keller 2005). EBs
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offer structural complexity which mimics in vivo events, as shown by Wnt-mediated axis
formation (Berge et al. 2008). The expression patterns of primary germ layer markers
such as Sox2, Brachyury, and Gata4, as well as markers of hematopoietic lineage
determination suggest that EBs accurately reflect in vivo murine germ layer formation
spatially and temporally (Leahy et al. 1999; Reviewed in Keller 1995, 2005). Due to
their accurate temporal and spatial modeling, they have been used to specifically model
cardiac (Doetschman et al. 1985; Sanchez et al. 1991), hepatocyte (Chinzei et al. 2002)
and, neural (Reviewed in Keller 1995, 2005) specification, each of which arise from a
different germ layer. They have also been used as a model to study epigenetic regulation
and modification in developing embryos (Kremenskoy et al. 2003). Based on the wellestablished literature regarding EBs as an accurate model for germ layer formation, we
selected this system to carry out our studies.
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Statement of Aims
The overall goal of this project was to further define the role of cJun in the regulation of
Oct4 and embryonic stem cell potency. Previous evidence in our laboratory suggested
that modulation of cJun/JNK signaling affected mESC potency, and that this could be
through upregulation of OCT4A expression. To address this question, we proposed the
following two aims:
1. Address the potential of cJun to transcriptionally regulate Oct4. Utilizing
bioinformatics, our lab has identified a putative AP-1 binding site in the Oct4
distal enhancer region. The presence of this site suggested that AP-1 family
members, including cJun, may participate in the regulation of the Oct4 gene. To
address this, luciferase assays were conducted in 293T cells with a reporter
construct containing the candidate AP-1 binding sequence of the Oct4 proximal
promoter (bp -2263-2257). The construct, -3066 +1, contains approximately 3 kb
that precede the translation start site of OCT4A (aa. 1, exon 1). The promoter
sequence was cloned into the pTA Luc reporter plasmid. Reporter activity was
measured in the presence of GFP, GFP cJun, and a GFP cJun mutant that has been
shown to be transcriptionally inactive (GFP cJun L40/42A). Additionally, we
utilized active Beta-catenin, a known activator of canonical Wnt targets alone or
co-transfected with each of the cJun constructs. Thirty-six to forty-eight hours
post transfection, cells were imaged for GFP expression to confirm successful
transient transfection, then the cells were analyzed with the Promega Dual Glo
Stop and Glo Kit to assess luciferase and Renilla production. Data was collected
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on the SpectraMax5L plate reader by Molecular Devices and analyzed by a oneway ANOVA followed by Tukey’s Multiple Comparisons.
2. Determine the role of cJun in cell fate determination of pluripotent, murine
embryonic stem cells. Previous work demonstrated that modulation of cJun
affects the potency of mESCs and murine embryonic carcinoma cells (mECCs)
(Groot et al. 1990; Liu et al. 2015; Veluscek et al. 2016; Hosawi et al. in prep).
To better characterize the role of cJun and JNK signaling on mESC potency and
cell fate decision making, cJun/JNK signaling was modified through transient
transfection of J1 embryonic stem cells with ef1-GFP, ef1-GFP cJun, the
transcriptionally inactive cJun mutant ef1-GFP L40/42A, or treatment with
chemicals that modify the JNK signaling pathway (anisomycin, a JNK activator,
and the JNK inhibitor, SP600125). Treated stem cells were harvested 36 hours
post-transfection, or two and four hours post-drug treatment, as well as
differentiated into embryoid bodies (EBs). A fraction of these samples harvested
prior to differentiation were utilized for immunocytochemistry(ICC) and western
blot analysis to assess early changes in potency markers, including OCT4A. The
remainder of the samples were used to generate embryoid bodies (EBs), an in
vitro model of early gastrulation, which display markers indicative of the three
primary germ layers, thus allowing us to study the influence of cJun on
development. It was expected that because modulated Oct4 can select toward
either the mesoderm or endoderm (Rodriguez et al. 2007), the regulatory effect of
cJun on Oct4 will play a crucial role in the early steps of lineage commitment.
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The EB samples generated from J1 mESCs were utilized for western blot analysis
to detect changes in markers for the different germ layers. Based on these results
transfected cells were differentiated into beating cardiomyocytes, through a
hanging drop intermediate, to further assess differentiation potential.
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MATERIALS AND METHODS
Cell Culture and Maintenance of 293T Cells
Lenti-X™ 293T cells were obtained from Clontech (Mountain View, CA). They
were grown on adherent tissue culture grade dishes at 35,000 cells/cm2 and grown at 37℃
in 5% CO2 in 1X DMEM from Gibco (Ref. 11995-065) and 10% Hyclone® Fetal Bovine
Serum (FBS) (cat. SH30070.03). Cells were subcultured at approximately 90%-95%
confluency by washing with 1X Sterile PBS (Gibco® Life Technologies, Grand Island,
New York, ref. 14190-235) and treating with 0.05% Trypsin-EDTA (Gibco® Life
Technologies, Grand Island, New York, ref. 25300-054). Cells were spun down at 1400 x
g for 5 minutes at room temperature, resuspended in 1-3ml of prewarmed media and
tested for viability using a Trypan Blue Assay (Gibco® cat#15250-061).

Basic Cell Culture of J1 Murine Embryonic Stem Cells
Murine Embryonic cell line, J1, was purchased from American Type Culture
Collection (ATCC) (Manassas, VA). Cells were grown on a layer of murine embryonic
fibroblast (MEF) cells treated with mitomycin C to inhibit cell division and optimize
growth factor secretion. MEFs were plated at 50,000 cells/cm2. The mESCs were grown
in ES-DMEM media containing DMEM base, 2.0 mM L-alanyl-L-glutamine, 1X
nonessential amino acids, 0.1 mM 2-mercaptoethanol, 50 units/ml Lif and 15% fetal
bovine serum (FBS). The MEFs were plated prior to passaging the mESCs, in 1X
DMEM base from Gibco® with 10% Hyclone® FBS. For each passage cells were washed
with sterile PBS, treated with 0.05% trypsin, spun down at 700 x g for 5 minutes at room
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temperature and resuspended in warmed fresh mESC media. A trypan blue assay was
performed to assess viability and all cells were plated at 30,000 cells/cm2 and kept at
37℃ and 5% CO2.
Transient Transfection of 293T cells and J1 Murine Embryonic Stem Cells
Prior to transfection, tissue culture dishes were coated with 0.1% gelatin in water
from Stem Cell Technologies (catalog # 07903) and incubated at room temperature for 30
minutes. Transfection cocktails were prepared following manufacturer's’ instructions for
the Lipofectamine® 3000 kit (Invitrogen Thermo Fisher Scientific cat#. L3000-015) using
Gibco® OPTI-MEM® I(1X) (Grand Island, New York, cat # 31985-062). Each
transfection cocktail contained one of the following plasmids: pLVX-EF1a-AcGFP1cJun, pLVX-EF1a-AcGFP1-L40/42A or pLVX-EF1a-AcGFP (total of 2.5 µg DNA per 1
x 106 cells). Cells were harvested as described above and 1x106 cells were added to each
cocktail with additional cells for “no treatment” controls. The reaction was optimized
using 2.5 μg total DNA per 1 x 106 cells, 3.75 μl of Lipofectamine 3000 and 5 μl of
P3000 per cocktail. The DNA-cell cocktails were then spun at 37℃ at 700 x g for one
hour. Cells were then gently resuspended and plated on to the gelatin coated dishes or
coverslips for ICC, incubated for 36 hours, then fixed or harvested for protein and/or
embryoid body formation.

Luciferase Assays in 293T Cells and J1 Murine Embryonic Stem Cells
Human embryonic kidney 293T cells or J1 mES cells were cultured as described
above. 293T cells were plated at 30,000-35,000 cells/cm2, grown to 90% confluency and
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harvested as described above. Cocktails were then set up containing the appropriate
Oct4-Luciferase reporter construct, a Renilla control plasmid and one of the following
GFP expression constructs: pLVX-EF1a-AcGFP1-cJun, pLVX-EF1a-AcGFP1-L40/42A
or pLVX-EF1a-AcGFP. Each GFP expression construct was also tested in the presence
of an additional Beta-catenin plasmid or a filler DNA plasmid (pcDNAgfp). The
lentiviral vector utilized to clone each of the cJun variants was developed by Clontech
and is expressed in many cell lines including most murine embryonic lines. Positive
control wells were transfected with the pTALucSUPER TOP plasmid +/- Beta-catenin to
ensure that the luciferase reagents were working properly. Additionally, three wells of
cells without any transfected DNA were processed through the luciferase assay to
determine biological background signal. The above transfection protocol was used,
however the cJun mutants/Beta-catenin plus filler DNA or cJun construct with Betacatenin only comprised 20% of the total DNA (split evenly 10%cJun, 10% filler/Betacatenin). The pTALucOct4 plasmid was generated by cloning 3000 bp (the entire
proximal promoter region (0 to -1.39 kb) as well as a portion of the distal promoter (-1.4-3.0 kb) of the Oct4 promoter sequence into the pTALuc plasmid, which contains a
putative AP-1 binding site at bp-2257 identified by our laboratory through bioinformatic
analysis, and three TCF/LEF binding sites previously demonstrated to be responsive to
active Beta-catenin (Li et al. 2012). This construct comprised 78% of total DNA and a
Renilla reporter driven by the constitutive SV40 promoter (pRL-SV40, Sherf et al. 1996)
was 2.7% of total DNA and utilized as an internal control. Plasmid DNA was prepared as
needed following manufacturer's instructions from the Clontech NucleoBond® Xtra Midi
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Plus EF kit (ref. 740422.10). Cells were incubated for 36-48 hours post-transfection and
imaged with the Ziess Axio Observer Z1 Fluorescent Microscope at 20X total
magnification to detect GFP expression. Promega’s Dual-Glo® Luciferase Assay System
(ref. E2940) was used as instructed by the manufacturer to carry out the Luciferase
Assay. Data was collected using a SpectraMaxL plate reader, from Molecular Devices,
with the following parameters: 1-minute dark adapt, 5 second shake before reading and
10 second total well scan per well.

Embryoid Body Formation
cJun/JNK signaling was modified in mESCs through either 1.) transient
transfection with pLVX-EF1a-AcGFP1-cJun, pLVX-EF1a-AcGFP1-cJun-L4042A or the
vector alone or 2.) treatment with anisomycin, SP600125 or DMSO. Thirty-six hours
post transfection or two to four hours post drug treatment the cells were harvested from
gelatin coated dishes for embryoid body formation. 1 x 106 cells per treatment, per time
point were resuspended in differentiation medium containing 15% Hyclone® FBS
(catalog # SH30070.03), 0.1mM MEM Non-Essential Amino Acids (catalog # 07600),
2.0mM L-Glutamine 200 (catalog # 07100), 1.0mM MTG (1:10 Dilution in DMEM)
(Sigma #M-6145) and 1X DMEM to final volume. The cells were then plated to ultralow adherent tissue culture dishes, fed every other day and harvested either 4 days (96
hours) or 6 days (144 hours) post-plating for protein extraction and western blot analysis.
For the drug treated cells, the appropriate concentration of drug was added to the fresh
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media each time the cells were fed. Low adherent cultures were incubated at 37℃ with
5% CO2.

Nuclear Protein Extraction, BCA Protein Assay and Immunoblot Blot
Nuclear extractions were performed on transiently transfected (36 hours posttreatment) or chemically treated (2-4 hours post-treatment) J1 mESCs and embryoid
bodies harvested from ultra-low adherent tissue culture dishes on days four and six. All
samples were harvested according to the protocol listed in cell maintenance. The NEPER® Nuclear and Cytoplasmic Extraction Reagents kit by Thermo Scientific (Prod #
78835, Rockford, Il) was used according the manufacturer's instructions.
A BCA protein concentration assay was conducted on all extract samples to
ensure proper concentration and loading for westerns. The assay was carried out
according the manufacturer's instructions for the Pierce BCA Protein Assay Kit by
Thermo Scientific (Ref 23225, Rockford, Il).
6X SDS sample buffer was added (to a final 1X concentration) to each sample
and heated at 95℃ for 5 minutes. For nuclear extracts, an average of 4-5 µg of protein
was loaded per sample. For cytoplasmic extracts, approximately 10 µg of protein was
loaded per sample. 6 µl of EZ-Run™ Pre-Stained Rec Protein Ladder was also loaded
(Ref. BP3603-500). Novex™ 10-20% Tris-Glycine Gel (EC6135BOX, Rockford, Il)
gradient precast gels was run at 110V for approximately 2 hours at room temperature in
1X SDS running buffer. A Millipore PVDF membrane (cat. IPVH00010) was used for
the transfer. Membranes were activated for 2-3 minutes in 100% methanol. Both the gel
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and the membrane were allowed to equilibrate for several minutes, without contact, in
cold transfer buffer (1X Tris-Gly Buffer, 20% Methanol and ddH2O to volume) while the
transfer apparatus was prepared. The transfers were run at 20V, for two and a half hours
at 4℃. Membranes were placed in blocking buffer (1X TBST, 1% BSA and 0.1% nonfat
milk) for 15 minutes on a rocker. Primary antibodies including: cJun, phosphorylated
cJun, eGFP, JNK, phosphorylated JNK, OCT4, OCT4A, GATA4, Brachyury, SOX1,
Nanog, SOX2 and GAPDH were prepared at appropriate dilutions in block and incubated
overnight at 4℃ (Supplemental Table 1). The membranes were washed three times
with 1X TBST for 5 minutes each on a rocker. Secondary antibody was added at a
1:2000 dilution in blocking solution and incubated for 1 hour at room temperature. Three
additional 7-minute washes with 1X TBST were done prior to development.
WesternSure Premium Chemiluminescent Substrate (cat. C50528-02) was prepared at a
1:1 ratio immediately prior to imaging with the Li-Cor-C-Digital machine on high
sensitivity. To obtain a GAPDH loading control for each gel run, membranes were
gently stripped for 5-10 minutes after imaging with medium stripping buffer (Thermo
Fisher Scientific, Waltham, MA, cat. 21059). They were washed three times for 5
minutes each with 1X TBST, blocked for 15 minutes and put into GAPDH primary
antibody overnight at 4℃. Secondary antibody and imaging steps remained the same.
Densitometry was performed on each blot to assess the fold change in protein relative the
GAPDH.
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Immunocytochemistry
Coverslips were coated with 2 μg/ml fibronectin (STEMCELL Technologies Inc,
Vancouver, BC, Canada) and incubated at 37℃ for 60 minutes. MEFs were then plated
to the coverslips and allowed to adhere for 24 hours. Next, mES cells were plated to
coverslips and fixed 36 hours post-plating with 4% paraformaldehyde in PBS for 5
minutes. Cells were washed with PBS twice for five minutes per wash. Nonidet™ P 40
Substitute (Sigma- Aldrich®, Louis, MO) was diluted in PBS to a working concentration
of 0.1% and used to permeabilize cells for 30 minutes at room temperature. Cells were
washed twice with PBS for 2 minutes and incubated for 30 minutes in blocking buffer
that consisted of 0.1% Triton™ X-100 (Sigma- Aldrich®, Louis, MO) and 1% goat
serum (Thermo Fisher Scientific, Waltham, MA) in PBS. Cells were incubated in
primary antibody including: cJun, OCT4A and OCT4 diluted in blocking buffer for one
hour and washed for five minutes in PBS three times (Supplemental Table 1).
Secondary was diluted in block and incubated at room temperature for one hour.
Coverslips were mounted using ProLong® Gold antifade reagents with DAPI (Life
Technologies, Grand Island, NY) to stain the nuclei, and allowed to dry at room
temperature overnight prior to viewing. For analysis, the Zeiss microscope and software
were used (Carl Zeiss Inc, Thornwood, NY). To detect DAPI the 350 nm excitation and
450 nm emission filters were used. Texas Red was used to offset for dual stains and
detected using 595 nm excitation and 615 nm emission filters whereas green fluorescence
(Alexa Fluor 488 or plasmid generated eGFP) was detected using 490 nm excitation and
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520nm emission filters. In all cases samples without primary antibody were generated to
account for background during processing of images.

Hanging Drop Embryoid Body Formation and Directed Differentiation to
Cardiomyocytes
After transfection, cells for each treatment were harvested from 0.1% gelatin
(Stem Cell Technologies, catalog # 07903), counted using a Trypan Blue Assay and then
an aliquot of 40,000 cells was removed. Bacterial grade dishes (Fisher Scientific,
Waltham, MA, cat. S35839) were used to create hanging drops. The bottoms were filled
with 10 ml of sterile PBS and 20 μl drops of cell suspension were placed on the lid to
cover the surface while maintaining separation between drops. Dishes were then closed
and incubated for 48 hours at 37℃ in 5% CO2 with the cell droplets inverted. After 48
hours hanging drop EBs were harvested by slowly adding media to pool the drops then
placing the suspension into a 15 ml conical tubes. Cells were allowed to settle for
approximately 5 minutes at room temperature then the media was aspirated off. Cells
were gently resuspended in differentiation media (see: Embryoid Body Formation above
for recipe) and plated to low adherent dishes. EBs were kept in ULA dishes for four and
six days before being plated back to adherent dishes for 10-15 days. EBs were fed every
other day as described above and checked daily to monitor for beating sites.

Data Analysis
Luciferase Assay: due to concerns regarding the variation of raw Renilla values,
an ANOVA was carried out, prior to normalizing the luciferase data, which showed that
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there was no significant difference following removal of outliers (data not shown). Next,
Luciferase signal was normalized with Renilla to generate F/R ratios per treatment, per
run which is represented as Relative Light Units (RLU). The F/R ratios were averaged
and a one-way ANOVA was used to determine significance. Tukey’s multiple
comparisons was used as post-hoc analysis to compare specifically between different
transfection treatments (n = 12). Significance was defined as a p-value of p < 0.05. Data
are shown as the mean Fold Change in normalized Luciferase Signal ± Standard Error of
the mean (SEM).
Immunoblot: protein expression was quantified by analyzing western blots using
densitometry software for the LiCor C-Digit scanner to assess fold changes in expression
relative to the GAPDH housekeeping gene. These fold changes were then compared
using a 2-way ANOVA or 3-way ANOVA (depending on how many variables were
being included in the analysis) followed by Tukey’s multiple comparison with
significance defined as p < 0.05. (n = 3 blots). Data are shown as Mean ± SEM.
Immunocytochemistry: For transfected cells, ICC was quantified by counting the
number of GFP positive cells, the number of OCT4A positive cells, and the number of
cells co-expressing GFP and OCT4A (n = 6 slides per treatment). A ratio of coexpressing cells:GFP positive cells was generated for each treatment and analyzed with a
non-parametric Friedman test. eF1-GFP treated cells were considered as the baseline to
compare cJun and L4042A using Dunn’s multiple comparison. Significance was
reported as p < 0.05. Data are shown as Mean ± SEM.
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Differentiation: Beating cardiomyocytes were analyzed using a mixed effects
model in R to account for EBs as a random factor and the number of EBs per treatment,
as it varied by experiment (though the initial number of cells per treatment was the same
prior to EB formation) with beating as the dependent variable. Based on the resulting
model, the data were graphed and significance was determined using a Satterthwaite
Approximation and p < 0.05. (n = 3 wells per treatment).
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RESULTS

A Regulatory Role for cJun in the Activation of the Oct4 Promoter
Bioinformatic analyses conducted by others in our laboratory identified an AP-1
binding site 2257bp upstream of the murine Oct4 transcription start site, suggesting
cJun might regulate Oct4 expression. To test this, we created a luciferase reporter
construct containing bases +1 to -3000 of the Oct4 promoter region. In addition to the
putative cJun binding site, this region also includes the entire Oct4 proximal promoter
(+1 to -1.39 kb), a portion of the Oct4 distal promoter (-1.4 to -3.2 kb), and three
TCF/LEF binding sites previously demonstrated to be responsive to active Betacatenin: -2032/2026; -1661/1655; and -881/875 (Li et al 2012). 293T cells were
transfected with 1. eF1-GFP, eF1-GFP –cJun (referred to as GFP cJun), eF1-GFP cJun
L40/42A (referred to as L4042A); 2. either pcDNA3-GFP or pcDNA3-MT BCA
(activated Beta-catenin); 3. pTALucOct4, and 4. a Renilla plasmid driven by the SV40
promoter (pRL- SV40) (Figure 3A, Supplemental Figure 1A-B). Additional wells of
293T cells were transfected with TOP FLASH with and without activated Beta-catenin
as a positive control for the assay. Luciferase assays were performed forty-eight hours
post transfection after GFP imaging confirmed high transfection efficiency (85%)
(Figure 3B, Supplemental Figure 2A-B).
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Figure 3. cJun Binds and Activates the Oct4 Promoter in 293T Cells
A. Diagrammatic representation of the plasmid vectors used to clone the Oct4 reporter
construct (left) the eF1-GFP vector (center) and the GFP-cJun constructs (right). B.
Transfection efficiency of 293T cells 48 hours post-transfection was approximately
85% or greater. Cells were imaged at 10X with the Zeiss Axio Observer and identified
by GFP expression prior to luciferase assays. Representative images are shown. C.
Luciferase data are represented as the average Luciferase to Renilla ratio to represent
the normalized luminescence of the reporter. A One-Way ANOVA followed by
Tukey’s HSD was used to compare promoter activation across different transfected
samples (n = 12). Activated Beta-catenin significantly increased promoter activity
compared to GFP cJun validating a role for Wnt signaling in the regulation of this Oct4
promoter construct(p<0.001***). GFP cJun significantly increased promoter activity
compared to the empty eF1-GFP vector (p<0.01**) suggesting that it too can affect
Oct4 promoter activity. The transcriptionally inactive mutant construct, GFP L4042A,
was not significantly different from the control vector. When GFP cJun and Betacatenin were co-transfected with the Oct4 promoter construct, they synergized and
significantly increased the reporter activity compared to GFP cJun alone (p<0.001***),
demonstrating a cooperative role for cJun and canonical Wnt signaling. The addition of
Beta-catenin to the L4042A mutant did not increase activity, but rather showed a
significant reduction in activity compared to GFP cJun (p<0.001***), demonstrating the
importance of transcriptionally active cJun to Bet-catenin activation of the Oct4
promoter.
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Transient expression of GFP, GFP cJun, and GFP L4042A from the plasmids was
confirmed by cJun and GFP immunoblot, as previously described (Hosawi et al in prep.)
(Supplemental Figure 4). Tukey’s HSD was used as post-hoc analysis to compare
promoter activation across different transfected samples (n=12) and data are shown as
Mean ± SEM (Figure 3C).
Our results showed that like Li et al. (2012), transfection of active Beta-catenin
significantly increased promoter activation by an average of nearly four-fold (3.6 ±
0.62), validating this plasmid as a reliable measure of Oct4 promoter activity.
Transfection of GFP cJun increased the Oct4 reporter construct activity by
approximately two- fold (2.2 ± 0.65), a significant increase when compared to our
vector control, eF1-GFP (p<0.001***). The cJun mutant GFP L4042A did not increase
luciferase expression. Rather, it slightly decreased the activity of the reporter construct
(0.8 ± 0.23). When cJun and Beta-catenin were transfected together, there was a
striking increase in promoter activation (5.8 ± 1.38) significantly greater than that of
GFP cJun alone (p<0.001***). In contrast, when the L4042A mutant was cotransfected with Beta-catenin the average activation of the reporter construct was
roughly equal to that of the eF1-GFP vector (1.0 ± 0.4). That we see a significant
increase in Oct4 promoter activity with the combination of cJun and active Betacatenin, which is diminished upon use of L4042A instead of wild-type cJun, suggests
that cJun is able to affect Wnt activation of the Oct4 promoter.
Having demonstrated the regulation of the Oct4 luciferase construct by cJun
in 293T cells, we were interested to see if the results of the assay would be changed
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if performed in murine embryonic stem cells. Knowing transient transfection is less
efficient in this cell type, we first transfected J1 mESCs with our robust TOP
FLASH reporter construct in the presence of Beta-catenin. Unfortunately, while we
were able to achieve approximately 350-fold-increase in TOP FLASH reporter
activity with 293T cells, the mESCs did not show increased plasmid activity. We
suspect that the lower transfection efficiency (estimated as mESCs = 30%, 293T =
90%) contributed largely to these results and did not pursue the analysis of cJun
regulation of the Oct4 luciferase construct in mES cells any further (Supplemental
Figure 3).

Transient cJun Specifically Increases OCT4A Expression in J1 mESC
The luciferase assay results suggested cJun could increase the expression of
Oct4 mRNA. To test this hypothesis, J1 mESCs were transfected with GFP, GFP
cJun, or GFP L4042A. Thirty-six hours later, transfection efficiency was evaluated
by GFP imaging. Although transfection efficiency was quite low (approximately
30%), the cells were harvested for protein analysis (Figure 4A). Expression of the
GFP constructs was verified by immunoblot with antibodies for murine cJun and
GFP. All samples expressed endogenous cJun (37 kDa), with levels slightly higher
in those transfected with GFP cJun and GFP L4042A. This was expected, as cJun
binds its own promoter via a consensus AP-1 site to regulate activity. Both
antibodies also revealed a band at approximately 70 kDa, the size of the GFP cJun
and GFP L4042A fusion proteins. The protein lysates from cells transfected with
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GFP had a 27 kDa protein appear with the GFP antibody only, which is the expected
size of eGFP. (Figure 4B).
Having confirmed the expression of the GFP and GFP cJun proteins, we
performed an immunoblot to evaluate OCT4 expression. Two different OCT4
antibodies were used: one that recognizes all isoforms of the protein (noted Oct4all in
figures) and one that only binds to the first exon of the protein, which is only
included in the OCT4A isoform. Murine embryonic stem cells transiently expressing
either GFP cJun or GFP L4042A samples showed a modest increase in OCT4A
protein signal relative to GAPDH while eF1-GFP and untreated mESCs showed
much less OCT4A (Figure 4C). The signal was measured using densitometry, which
demonstrated that the GFP cJun construct did increase OCT4A expression more than
the L4042A mutant, however the difference did not yield statistical significance.
To confirm the cells which successfully expressed the cJun plasmid were in
fact the same cells over-expressing OCT4A, we performed an immunocytochemistry
experiment. We identified transfected cells using the FITC channel since our cJun
plasmids were cloned into a vector with a GFP-fused promoter. We then stained for
either OCT4A or OCT4all (Texas Red). The results showed that the cells expressing
GFP cJun demonstrated increased expression of OCT4A in the nucleus, while cells
transfected with eF1-GFP did not show over-expression of OCT4A above
background (Figure 4E).
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Figure 4. Transfected cJun is Detected by Western Blot and Leads to an Increase in
OCT4A
A. J1 mESCs were transiently transfected with GFP, GFP- cJun, or GFP L4042A
and imaged for GFP expression 36 hours later. Cells were imaged using brightfield
and the FITC channels. (scale bar = 25µm, bottom row) (scale bar = 50µm, top row).
eF1-GFP appears the brightest, and most efficiently transfected, as it is a
cytoplasmic signal. Both cJun and L4042A localize to the nuclei and therefore are
harder to detect within the colonies. B. Transfected mES cells were harvested for
protein analysis to confirm successful over-expression of plasmids. The results
show GFP (27 kDA) and GFP cJun (70 kDA) in cells transfected with EF1-GFP or
EF1 GFP- cJun/L4042A, respectively. All samples express endogenous cJun (39
kDA) and GAPDH C. cJun and L4042A transfected samples showed a modest
increase in OCT4A protein expression relative to eF1-GFP and untreated controls.
Overall OCT4 levels did not appear to vary across samples. GAPDH was used as a
loading control (n = 3). D. Co-expression of OCT4A expression with GFP, GFP
cJun or GFP L40/42A was quantified by counting the number of GFP positive cells
(marked by white arrowheads) that displayed OCT4 expression above the levels
expressed in untransfected cells. Data are represented as the ratio of co- localized
cells to GFP positive cells per treatment. A Freidmann Test was used followed by
Dunn’s Multiple Comparisons which revealed a significant increase in colocalization of cJun treated cells with OCT4A compared to GFP (p < 0.0001****)
and GFP L4042A (p < 0.001***) (n = 6). E. Immunocytochemistry demonstrates
increased OCT4 protein in cells expressing GFP cJun. Transfected cells (GFP) and
OCT4A overexpression (Texas Red) are marked by white arrowheads. Levels of
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OCT4A protein above those in non-transfected cells were only documented in cells
expressing GFP cJun or GFPL4042A, however not all GFP-L4042A expressing cells
showed co-localization of OCT4A. (n = 6). F. Immunocytochemistry was carried
out with OCT4all (Texas Red) and transfected cells were identified by GFP
expression. GFP positive cells are identified by white arrowheads. Total OCT4
expression did not appear to be greatly altered across samples (n = 6).
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Cells expressing the GFP-L4042A construct did show some co-localization,
however not all GFP positive cells over-expressed OCT4A. We then quantified the
number of cells which were GFP positive (successfully transfected), had OCT4A
expression above endogenous levels, and the number of cells which co-expressed
OCT4A and GFP. Our results showed cells expressing GFP cJun had significantly
increased nuclear expression of OCT4A compared to either eF1-GFP
(p<0.0001****) or L4042A (p<0.001***) cells (Figure 4D). This was not the case
in the immunocytochemistry for OCT4, which had no notable difference in
localization and expression beyond background levels across all of the transfected
samples (Figure 4F).

Transient cJun Expression is Associated with an Increase in GATA4
OCT4A is the isoform classically responsible for regulating pluripotency
(Nichols et al. 1998, Niwa et al. 2000, Velkey and O’Shea 2003). To see if the
increases in OCT4A we observed in GFP cJun transfected cells could affect the
developmental fate of mES cells, we evaluated expression of germ layer markers in
embryoid bodies (EBs) derived from GFP, GFP cJun or GFP L4042A transfected
mESCs (Supplemental Figure 5). Day four and day six EBs were imaged and
harvested for protein to analyze expression of GATA4 (endoderm), Brachyury T
(mesoderm) and Sox1 (ectoderm) (Figure 5A). Though there was no selection to
induce the incorporation of these expression constructs into the genome; modest GFP
expression was still detectable at both time points (Supplemental Figure 6). We
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analyzed GATA4 expression, specifically, and found that it was significantly
upregulated in the Day 6 EBs, regardless of treatment, compared to Day 4 (p <
0.05*) (Figure 5B). Individual germ layer marker expression was evaluated based
on expression relative to GAPDH by immunoblot followed by densitometry and
normalized values were shown as the Mean ± SEM (Figure 5C-D). For EBs
cultured in low adherent conditions for four days (referred to as Day 4 EBs),
Brachyury expression levels were relatively constant across treatments
(Supplemental Figure 7C). Sox1 and GATA4 were highest in untreated cells
(Sox1=0.070±0.054, GATA4= 0.085±0.048). GATA4 expression was relatively
similar in eF1- GFP (0.048±0.011) and cJun (0.050±0.032) samples, with L4042A
just slightly lower (0.036±0.013). Interestingly, Sox1 expression was decreased in
cJun samples (0.044±0.016) and L4042A (0.037±0.005) compared to eF1-GFP
(0.076±0.035).
Day 6 untreated EBs expressed 1.77±0.137 GATA4, 0.139±0.033 Brachyury
and 0.035±0.010 Sox1 (Supplemental Figure 7D). Corresponding GFP samples
produced slightly elevated germ marker expression compared to untreated cells
(GATA4=0.161±0.124, BRY= 0.161±0.070, Sox1=0.050±0.0009), however the
standard error was still quite large. Samples expressing GFP cJun appeared to have
the greatest mean expression of all three germ layer markers after six days in low
adherent culture. Specifically, GATA4 expression (0.257±0.150) showed a
noteworthy increase of approximately 1.5 times greater than untreated EBs. Brachyury
expression appeared constant across all treated samples, with untreated cells
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expressing the lowest amount. Sox1 expression followed a similar trend wherein cJun
samples expressed 0.068±0.036 compared to untreated and GFP samples.
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Figure 5. Increased cJun and OCT4A Protein Levels Correlate with an Increase in
GATA4
A. Western blot analysis revealed a striking increase in GATA4 expression when
cells were transfected with cJun prior to embryoid body differentiation. Brachyury
levels appeared relatively constant while Sox1 appeared increased in both the no
treatment and eF1-GFP samples after four days of differentiation. Additionally,
Sox1 appeared to be increased in the Day 6 cJun sample. Both Sox1 and Brachyury
had variable expression patterns across replicates. GAPDH was used as a loading
control. (n = 3) B. Densitometry was utilized to quantify expression of GATA4,
Brachyury and Sox1 relative to GAPDH expression (shown as ratio of GAPDH:
protein of interest). A three-way ANOVA was utilized to compared germ layer
expression per treatment per days differentiated (Day 4 versus Day 6) followed by
Tukey’s Multiple Comparison which showed a significant increase in all germ layer
markers in the Day 6 samples relative to the Day 4 samples (p < 0.05*) (n = 3). C.
Two-way ANOVA followed by Tukey’s Multiple Comparisons was used to examine
germ layer expression per treatment after four days of differentiation. (n = 3) D.
Two-way ANOVA followed by Tukey’s Multiple Comparisons was used to examine
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germ layer expression per treatment after six days of differentiation. While GATA4
after cJun treatment appeared higher, there was a great deal of variation within
samples which likely contributed to a lack of statistical significance. (n = 3). E.
Schematic representation of selected annotated regions of Gata4 from Mus
musculus. (NCBI Accession NC_000080.6:c63271715-63198914). The upstream
promoter has two well- characterized enhancer regions 1b and 1a (green) at -5 Kb
and -250 bp respectively relative to the transcription start site (black arrow). The
second intronic region, which begins approximately 5 kb after the transcription start
site and spans a 1.1 kb region, contains an OCT4 consensus binding site (sequence
shown top left), two AP-1 binding sites (bottom left and top right), and a FoxA2
binding site (bottom right). This enhancer region has been shown to be conserved
for human and mouse (Rojas et al. 2010).
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L4042A expressed nearly identical levels of GATA4 (0.163±0.097), Brachyury
(0.157±0.055) and Sox1 (0.053±0.0008) relative to the eF1-GFP samples. This
suggests that cJun is able to modify the differentiation of mES cells.
To begin elucidating a molecular link between OCT4, cJun and GATA4 we
carried out a preliminary bioinformatics analysis. Within the second intronic region
of gata4, which spans 1.1 kb area between the second and third exons, there is a
highly conserved enhancer sequence which contains a FoxA2 binding site to specify
the formation of foregut endoderm (Rojas et al. 2010). Approximately 1 kb
upstream of the FoxA2 binding site, we found several AP-1 binding sites and one
OCT4 consensus binding site, however there were no sites present in the promoter
(Figure 5E). The presence of these binding sites offer evidence that OCT4 and cJun
can interact directly with gata4 to alter its expression and subsequent cell fate.

Transient cJun Expression Increases Cardiomyocyte Formation
GATA4 expression is a marker for endoderm formation, but is also essential
for the formation of cardiac mesoderm (Narita et al. 1997, Holtzinger et al. 2009).
These data coupled with the knowledge that slight changes in OCT4 levels have the
ability to increase primitive endoderm and mesoderm formation suggested we might
analyze differentiation to the myocardial lineage. Embryoid bodies derived from
hanging drops are an established model for differentiation to cardiomyocyte
formation, so we examined cardiomyocyte formation of EBs formed by hanging drop
with mES cells transfected with GFP, GFP cJun or GFP L40/42A (Figure 6A). The
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cells were the monitored for beating clump formation over a 10-day period (Figure
6B). Cells that received no plasmid DNA (untreated) and were kept in low adherent
conditions for four days were utilized as the baseline to compare the mean number of
beating sites over the 10-day period (n = 3) (Figure 6C).
After four days in low adherent culture, cJun treated samples had an average
of 5.00 ± 0.25 (Mean ± SEM) beating sites, which was greater than the average
number of beating colonies compared to the GFP vector control sample (2.77 ± 0.34)
(p < 0.001***). Untreated cells also had a greater average number of beating sites
(3.57 ± 0.42) compared to the GFP control (p < 0.05*). Day 6 cJun samples had a
greater mean number of beating sites (3.3 ± 0.05) compared to untreated samples (0.6
± 0.34) (p < 0.01**), GFP samples (2.24±0.36) (p<0.05*) and L4042A samples (2.84
± 0.28) (p < 0.05*). Beating cardiomyocytes derived from the GFP cJun expressing
EBs appeared to sustain their beating colonies beyond day 7 of monitoring, when both
the untreated and GFP samples had ceased (Figure 6B). L4042A day 6 samples,
unlike the other treatments, did not begin beating on day one of monitoring,
suggesting a possible delay in differentiation. L4042A samples did, however,
continue beating after the untreated and GFP samples stopped, albeit at lower
numbers than cJun treated samples. Taken together, these data demonstrate that an
increase in cJun expression can potentially increase cardiomyocyte beating.
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Figure 6. Increased cJun and GATA4 Correlate with Increased Beating Cardiomyocytes
A. Schematic of the experimental approach for cardiomyocyte differentiation. B. After four (pink circle) or six (blue
triangle) days in ultra-low adherent culture conditions, cells were plated and maintained in cardiomyocyte differentiation
media for 10 days (x-axis). Beating clusters were counted and monitored daily (left y-axis) for each transfected sample
(right y- axis). As represented in this graph, untreated cells and cells transfected with cJun produced more beating colonies
on Day 1 than eF1-GFP or L4042A samples. Over 10 days cJun treated cardiomyocytes appeared to maintain the greatest
number of beating colonies, specifically from the group kept in low adherent conditions for six days. C. A lmer model
was fit and followed with a Satterthwaite Approximation to assess the average beating per treatment, per days in low
adherent culture, per number of EBs plated for cardiomyocyte formation. After four days of low adherent conditions cJun
samples had the greatest mean beating colonies compared to eF1-GFP (p < 0.001***). There was no significance between
cJun and either L4042A or untreated samples after four days in low adherent culture. The untreated cells (shown as NT)
also had significantly more beating colonies than the eF1-GFP sample (p < 0.05*). After six days in low adherent
conditions, cJun still had the greatest number of beating colonies relative to all other treatments (NT = p < 0.01**; eF1GFP = p < 0.05*; L4042A = p < 0.05*) suggesting that overexpression of cJun plays a role in enhancing the production of
beating cardiomyocytes.
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Chemical Modulation of JNK Signaling Affects Potency, cJun Expression and OCT4
Jun-N-Terminal Kinase (JNK) phosphorylates cJun at two different serine
residues (S63 and S73) to increase cJun transcriptional activity (Smeal et al. 1992;
Czaja 2003). This phosphorylation requires the physical association of JNK with cJun
at leucine residues 40 and 42 (Sprowles et al. 2003). That the cJun mutant L4042A
impairs transcriptional activation of the Oct4 luciferase promoter construct, reduces the
effect of GFP cJun on the levels of GATA4 and SOX1 expressed in EBs, and the
differentiation of mES cells to cardiomyocytes, suggests JNK signaling might be an
upstream regulator of cJun in these processes. To test this hypothesis, two different
chemical modulators of JNK and cJun activity were tested to see how they might affect
the potency of mECSs. SP600125, a chemical inhibitor of JNK kinase activity
(Bennett et al. 2001), was utilized to downregulate activity while anisomycin (fungalderived) was used to activate the kinase (Miroslav et al. 1999). To see if JNK activity
was necessary for cJun’s effects on embryonic stem cells, the cytoskeletal destabilizer
nocodazole was selected, as it has been shown to increase cJun expression independent
of increased cJun transcription or MAPK activity (Polak et al. 2006, Blau et al. 2012).
Murine embryonic stem cells were plated to gelatin in mESC media and treated
with one of the following: 10 µM SP600125, 10 ng/ml anisomycin, or 5 µg/ml
nocodazole. Both a no treatment and a DMSO-only control were included, as DMSO
is the solvent used for all three chemicals, and DMSO has been shown to alter the
transcription and differentiation of some cells (Friend et al. 1971; Nomura and Oishi
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1983; Juang and Liu 1987; Iwatani et al. 2006). Two hours post treatment the cells
were harvested for protein and analyzed by immunoblot.
Although the expected changes in cJun and JNK were detected, the effects on
OCT4 expression were modest and inconsistent across replicates (n = 3)
(Supplemental Figure 8). In light of this, we added an additional four-hour time point
and additional drug concentrations (50 ng/ml anisomycin) and again looked at
phosphorylated cJun (p-cJun), phosphorylated JNK (p-JNK), the overall endogenous
cJun and JNK content, as well as potency markers OCT4A and SOX2 (n = 4) (Figure
7). As expected, anisomycin increased the phosphorylation state of both JNK and
cJun, while nocodazole treatment increased the amount of phosphorylated cJun without
affecting JNK. The JNK inhibitor, SP600125, successfully decreased p-cJun and pJNK by western blot. These decreases also coincided with potency expression similar
to the untreated controls and DMSO controls.
Although there was still variation between replicates, all chemical treatments
affected OCT4 expression, but in different ways. At two hours Anisomycin showed a
decrease in OCT4A, while Nocodazole treatment increased OCT4A expression at four
hours. As seen by cJun transfection, neither drug treatment had a noticeable effect on
the overall levels of OCT4 in the cell.
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Figure 7. Drug-Induced Modulated cJun Expression Alters Expression of Key
Potency Markers
Two or four hours post-drug treatment cells were harvested for nuclear and cytoplasmic
protein extraction. Western blot analysis revealed a decrease in OCT4A expression
when cells were treated for four hours with a high dose of anisomycin. Nocodazole
increased OCT4A expression after four hours, while overall OCT4 expression (OCT4)
did not appear altered. SOX2 expression appeared altered across treatments after two
hours, however by four hours expression levels were relatively similar. Phosphorylated
cJun (p-cJun) and JNK (p-JNK) confirm that inhibition with SP600125 or stimulation
with anisomycin was successful within the two-hour incubation period. GAPDH was
utilized as a loading control. (n = 4).
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Immunocytochemistry was also carried out following two and four-hour
incubations with drug treatments as described previously. The cJun antibody revealed
increased cJun expression in both Anisomycin and Nocodazole treated cells two hours
post-treatment (Figure 8A). There was minimal change in OCT4 all expression across
treatments but a noticeable increase in OCT4A, suggesting that OCT4A is specifically
being upregulated while the overall OCT4 protein content remains consistent (Figure
8B).
The observed increase in OCT4A expression was seen only in the cells
overexpressing endogenous cJun in response to Anisomycin or Nocodazole (n = 3)
(Figure 8C). The increase in OCT4A seen with Nocodazole is consistent with what
was detected by western blot (Figure 7). OCT4 all expression, again remained
relatively unchanged across all samples (Figure 8D)
Taken together, these data suggest that the increase in OCT4A and cJun may
occur in a JNK-independent manner, however, JNK signaling does affect potency. To
look at the effect of cJun on OCT4 expression, via JNK- dependent and independent
expression, on cell fate we cultured these cells after two or four hours of exposure in
ultra-low adherent conditions (n = 4). We found that EBs did not form in the presence
of anisomycin or nocodazole, however SP600125 had limited effect on EB formation
(Figure 9). Because Nocodazole destabilizes the cytoskeleton, it is possible that cells
were unable to form critical cell-cell adhesions and therefore were unable to form EBs.
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Figure 8. Drug Modulation Shows Co-localization of cJun and OCT4A at 2 and 4
Hours Post-Treatment
A. Two hours post drug-treatment cells were fixed and stained for cJun (FITC),
OCT4A (Texas Red) and DAPI (blue) to detect co-localization within the nuclei
(indicated by white arrowheads). As expected cJun expression was lower in the
SP600125 treated cells, however it was dramatically increased under Anisomycin and
Nocodazole conditions. Scale Bar=15 µm (n = 3 replicates) B. Cells were stained for
cJun (FITC), DAPI (blue) and OCT4 all (Texas Red) after two hours of drug- treatment.
Both the SP600125 and no treatment samples had slightly elevated levels of OCT4 all
compared to the DMSO cells. Nocodazole, however showed a striking increase in
overall OCT4 levels compared to all of the other samples. Scale Bar = 15 µm (n = 3
replicates) C. Immunocytochemistry was also carried out four hours post-treatment for
cJun (FITC), DAPI (blue) and OCT4A (Texas Red). Co-localization is indicated by
white arrowheads. This a striking increase in OCT4A expression following nocodazole
treatment. Similarly, the higher dose of anisomycin showed an increase in OCT4A.
Scale Bar = 15 µm (n = 3 replicates) D. OCT4 all expression (Texas Red) was
examined four hours post-treatment and did not appear to change despite variation in
cJun expression (FITC) across samples. Scale Bar = 15 µm (n = 3).
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Figure 9. Increased cJun Expression by Anisomycin and Nocodazole Impede Embryoid Body Formation
Cells incubated for two hours with No treatment, DMSO, a JNK inhibitor (SP600125), a JNK activator (anisomycin) or an
anti-cancer drug (nocodazole) were differentiated for four days in low-adherent conditions. While the JNK inhibitor
samples formed embryoid bodies of comparable size to the controls (no treatment and DMSO), both anisomycin and
nocodazole only formed cell clumps of 30 cells or less (top). Scale Bar = 400m. This experiment was carried allowing the
cells to differentiate for six days, however additional time in culture yielded similar results (bottom).
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DISCUSSION

The goal of this study was to determine the ability of cJun to regulate the
expression of Oct4. Additionally, we sought to characterize the developmental
consequences of this relationship and how cJun transcriptional activity would affect cell
fate. Our results indicate that increased cJun can lead to an increase in OCT4 protein
expression, transcriptional activity and a subsequent increase in a GATA4+ population,
which is associated with increased formation of cardiomyocytes. That overexpression of
the cJun L40/42A mutant reduced the transcriptional and developmental effects of wild
type cJun overexpression suggests that the phosphorylation of cJun at serine 63 is
necessary for these results, even though modulation of the JNK signaling pathway did not
yield clear results. We believe this work will provide a necessary foundation for better
understanding the role of cJun during early embryonic development, specifically
endoderm and cardiac mesoderm formation.

cJun Increases Oct4 Promoter Activity
Increased expression of both Oct4 and cJun have been shown to reduce potency in
murine embryonic stem cells. Niwa et al. (2000) demonstrated that a less than two-fold
increase in Oct4 expression directs mES cells toward differentiation to primitive
endoderm and mesoderm and overexpression of cJun has also been shown to induce
differentiation of mES cells (Abujarour et al. 2010, Liu et al. 2015). Our data
demonstrating the transcriptional activity of our Oct4-luciferase reporter construct is
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significantly altered by the biochemical state of cJun in 293T cells support a model that
these two transcription factors might work together towards this end. Expression of GFP
cJun increased reporter activity by approximately two-fold compared to the eF1-GFP
control, while the transcriptionally inactive GFP L4042A mutant construct reduced
promoter activity of the Oct4-luciferase reporter construct compared to the eF1-GFP
vector alone, demonstrating the importance of phosphorylation of cJun, on basal levels of
promoter activity. This supports our previous bioinformatics analysis that identified an
AP-1 consensus site in the Oct4 distal promoter region, suggesting cJun may directly
increase Oct4 expression by binding the enhancer to increase mRNA production.
Though the effects of GFP cJun overexpression are somewhat modest, they are
within the range of the changes reported by Niwa et al. that affect mES potency.
Furthermore, that co-transfection of GFP cJun with active Beta-catenin increases reporter
activity more so than Beta-catenin alone, suggests a broader role for cJun in Oct4 gene
regulation and may be essential in further understanding the molecular regulation of
critical potency genes. Wnt signaling is a well-established and highly conserved regulator
of ICM potency and Toualbi et al. (2007) demonstrated the synergism of Beta-catenin
and AP-1 members, including cJun, when cyclin-D1 transcription is activated. Overall,
the binding partners of cJun appear to be critical in determining its activity.

Over-Expressed cJun Leads to Increased Expression of the OCT4A Isoform in Murine
Embryonic Stem Cells
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Previous work has demonstrated increases in cJun expression in ground state mES
cells reduce their potency, as evidence by reduced mRNA levels of pluripotency genes
including Oct4 (Liu et al 2015). Our luciferase assay results showed the opposite;
however, they were performed in 293T cells, which are derived from human embryonic
kidney cells immortalized with large T antigen. Therefore, we decided to evaluate
overexpression of cJun on Oct4 expression in mES cells cultured under standard mES
cell conditions. Unfortunately, our attempts to perform luciferase assays in mES cells
were unsuccessful likely due to low transfection efficiency. Despite significant effort, we
were not able to achieve transfection efficiencies high enough for our positive control to
provide a signal above background (<20% of mES cells vs. > 90% of 293T ells).
(Supplementary Figure 3B). Therefore, we decided to evaluate OCT4 expression levels
in the presence of the GFP cJun or GFP L4042A construct. Though transfection
efficiency of the mES cells was significantly lower than that of 293T cells
(Supplemental Figure 3A), the expression levels of eF1-GFP, GFP-cJun, and GFPL40/42A were sufficient to detect by immunoblot, as was OCT4A; when GFP cJun is
over-expressed in mES cells, the overall OCT4 levels remain similar compared to eF1GFP treated and untreated samples, however OCT4A protein levels appear modestly
increased. This suggests a potential connection between the transcription of the OCT4A
isoform and cJun. This result was confirmed when mES cells transfected with cJun were
analyzed for OCT4 expression by immunocytochemistry: only cells overexpressing the
GFP-cJun construct had significantly increased levels of OCT4A. Furthermore, WT-cJun
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and endogenous OCT4A were co-localized in the nuclei of the same mES cells, which
would be necessary if cJun is increasing OCT4A expression directly.
When evaluated by immunoblot, OCT4A expression was also increased in the
presence of the GFP cJun L40/42A construct, but the immunocytochemistry analysis
showed a significant reduction when compared to GFP cJun, which does support the
luciferase assay data. Phosphorylation of L40/42A by JNK is known to be required for
transcriptional activity off of AP-1 sites associated with cellular proliferation (Jun
promoter), but it is not required by all promoters (e.g., MMP1) (Blau et al. 2012). Liu et
al (2015) reported that the L40/42 sites are not required for inhibition of iPSC generation
by cJun, but that the bZIP domain is. The full length cJun protein is known to have an
inhibitory function by dimerizing the inhibitor JDP2, which subsequently enhances iPSC
formation and also requires the bZIP domain (Liu et al. 2015). This raises the possibility
that, congruent with what Liu et al. discovered, Oct4 expression is regulated primarily
based on the binding partner utilizing the bZIP domain. Ultimately, this suggests the
regulation of Oct4 expression may involve the recruitment of partners that inhibit
transcription. A more thorough explanation of the role of JDP2 in this process and JNK
activity will be required to fully understand the regulatory function of cJun.

Overexpression of cJun results in increased GATA4 Expression
Overexpression of cJun in ground state mES cells has previously been shown to
affect germ layer marker expression (Liu et al. 2015; Veluscek et al. 2016). Because the
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liver and pancreas are derived from the endoderm and increased Oct4 has been linked to
mesoderm/endoderm differentiation, we examined the effect of over-expressed cJun on
the formation of the primary germ layers during gastrulation using an in vitro embryoid
body model.
One of the earliest choices made as cells move from the blastocyst through
gastrulation is the formation of the epiblast and primitive endoderm (PrE). It has been
shown that the transcription factor GATA6 controls the speed and proportion of PrE-fate
commitment, relative to epiblast formation, by mediating FGF/ERK signaling (Schrode et
al. 2014). Erk signaling, specifically, plays a crucial role in endodermal differentiation
by suppressing PrE (Hamilton and Brickman 2014) and therefore maintaining an intricate
balance between differentiation cues. As cells become committed to the epiblast,
GATA6 expression is altered and markers including GATA4, Brachyury (BRY) and
SOX1 emerge to indicate germ layer formation.
SOX1 is one of the earliest spatial/temporal indicators of induction toward neural
ectoderm (Penvy et al. 1998). While we did not detect striking changes in SOX1
expression, we did note that it was decreased in EBs transfected with GFP cJun
expression. We have previously seen that EBs formed from mES cells transfected with
GFP cJun does impede differentiation toward an ectoderm derived lineage (Hosawi et al.
in prep). Overexpression of the full length cJun protein has also been shown to be
sufficient for inducing apoptosis of sympathetic neurons (Ham et al. 1995; Ham et al.
2000), which could explain the lack of neuronal clusters originally observed by Hosawi et
al. (in prep). Brachyury expression, however, remained relatively constant regardless of
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treatment with cJun, suggesting perhaps cJun does not play an integral role in directly
specifying this lineage.
We did observe a striking increase in GATA4 protein in day 6 embryoid bodies
formed from mESCs transfected with WT-cJun prior to differentiation. GATA4 was also
increased in the EBs transfected with GFP L40/42A cells, but at a reduced level, again
suggesting phosphorylation at these sites increases cJun activity. Although the
densitometry values showed it was not significant, cJun treated samples did have the
greatest mean GATA4 expression following six days of low-adherent differentiation.
These data agree with a study performed by Liu et al. (2015) who showed that expression
of cJun in ground state mES cells increases GATA4 expression 24 hours post-induction.
A more sensitive approach, such as quantitative PCR (qPCR) may be beneficial in
elucidating a significant trend whereby GATA4 is clearly upregulated in cells overexpressing cJun at the mRNA level.

Overexpression of cJun During Embryoid Body Formation Increases Differentiation to
Cardiomyocytes
The increase in GATA4 expression we characterized in the GFP cJun EBs
suggested the EB differentiation potential could be affected. Previously in our lab we saw
that an increase in cJun caused impaired differentiation into insulin-secreting pancreatic
islet-like cells (Hosawi et al. in prep). Specifically, the neuronal projections between
clusters, which are derived from the ectoderm, exhibited inappropriate morphology and
reduced overall formation. The endoderm-derived portions of the cluster, however, were
able to form in the presence of over-expressed cJun. Conversely, when cells were
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transfected with the L4042A construct, the clusters were larger and displayed appropriate
neuronal morphology. These data coupled with the knowledge that slight changes in
Oct4 levels have the ability to increase primitive endoderm and mesoderm formation
suggested we might analyze differentiation to the myocardial lineage. GATA4 has been
known to contribute to the formation of cardiac mesoderm, so we examined
cardiomyocyte formation in vitro wherein cells were transfected, placed in hanging drops
and subsequently differentiated in low adherent conditions prior to plating for
cardiomyocyte formation.
Our data show that increased cJun through transfection ultimately led to an
increase in GATA4 and finally an increase in the number of beating colonies. Others
have shown that GATA4+ expression in embryoid bodies is sufficient to significantly
increase cardiomyocyte formation (Holtzinger et al. 2009). Interestingly, cardiac
mesoderm forms due to the production and secretion of cardiac-inducing factors from
endoderm-derived GATA4+ cells, rather than GATA4 expression within the mesoderm
cells themselves (Narita et al. 1997; Holtzinger et al. 2009). Moreover, GATA4 levels
are altered by BMP expression as cells of the foregut endoderm are guided toward a
hepatic fate while simultaneously selecting against a pancreatic fate (Rossi et al. 2001).
BMP4-deficient embryos generated through homologous recombination show that it is
required for mesoderm formation (Winnier et al. 1995). BMPs work in parallel with FGF
signaling from the cardiac mesoderm, which maintains Brachyury expression through
gastrulation (Schulte-Merker and Smith 1995), to guide endoderm derived foregut tissue
toward a hepatic fate (Rossi et al. 2001). In response, the GATA4+ endoderm population
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produces cardiac-inducing factors and ultimately are able to contribute to the temporal
and spatial generation of cardiomyocyte progenitors from associated mesoderm (Narita et
al 1997, Holtzinger et al. 2009). Taken together, these data present a model wherein
over-expressed cJun binds to the Oct4 promoter to increase transcription of the OCT4A
isoform and ultimately drive cells toward a specific endodermal fate.
Simandi et al. (2016) have shown that Oct4 is upregulated in response to
differentiation cues due to its ability to bind to low-accessible genomic regions and
activate enhancers which would otherwise remain unresponsive. Therefore, it is
important to confirm that the increase in Oct4 is essential for increased cardiomyocyte
formation, and not simply a byproduct of in vitro differentiation cues.

Furthermore, it is

crucial to confirm the necessity of increased Oct4 preceding differentiation. This can be
done through co-transfection of our WT-cJun construct and a RNAi construct designed to
target Oct4 transcripts. Previous reports have also shown that ablation of Beta-catenin in
embryonic endoderm causes a distinct shift toward pre-cardiac mesoderm while cJun-/mice have impaired cardiac development (Eferl et al. 1999; Lickert et al. 2002). It would
be of interest to examine the effect of co-transfection with WT-cJun and Beta-catenin on
cell fate, or treatment with GSK3, to further understand the role of Wnt signaling
particularly, in regards to cardiac specification. Additionally, since germ cell nuclear
factor (GCNF) functions as a repressor of Oct4 through direct binding of the proximal
promoter in non-germ line cells and subsequently silencing it during gastrulation
(Fuhrmann et al. 2001), it would be interesting to investigate the effect of over-expressed
cJun on GCNF. Overall, there is a great deal of cross-talk between major signaling
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pathways as the embryo undergoes gastrulation and proceeds with development that
remain to be studied.
Upstream Modulation of the JNK/cJun Signaling Pathway
Building on our previous data, we treated mES cells with chemicals to modulate
the JNK pathway in hopes of elucidating the molecular mechanism through which cJun is
activated. Unfortunately, these data were met with mixed results. Similar to the results
seen with the transcriptionally inactive L4042A construct, samples treated with low doses
of SP600125 showed minimal difference in OCT4 expression compared to untreated
controls. It has previously been shown that cells derived from either JNK1-/- or JNK2-/embryos were able to undergo self-renewal, however, their ability to undergo lineage
specification was severely impaired (Xu and Davis 2010) demonstrating that ultimately
JNK does play a critical role if inhibition is aggressive enough. Samples treated with
anisomycin did show a promising increase in endogenous phosphorylated cJun; however,
the expression of OCT4A was highly variable and cells did not efficiently form embryoid
bodies to assess the germ layer potential. It is possible that the discrepancies in OCT4A
expression were due to different pathways converging on cJun to activate it. Hosawi et
al. showed that differentiation of anisomycin treated mESCs resulted in impaired
pancreatic islet-like clusters, similar to cells transfected with WT-cJun (in prep). This
striking parallel in results suggests that while JNK may not be the only pathway active, it
does play a role. Because both JNK and p38 are able to phosphorylate cJun through
JNK/MAPK and mTOR signaling respectively, it would be of interest to inhibit them
separately. This could elucidate a better understanding of which protein is necessary, and
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perhaps solely sufficient, to drive the context-specific increase in OCT4A and endoderm
formation.
Modulation of cJun Expression by Increased Translation Also Increases OCT4A
Expression
Preliminary results conducted using the anti-cancer drug nocodazole were also
variable. Nocodazole functions by disrupting the cytoskeleton to prevent spindle
formation, however previous work has shown that it actually causes an increase in cJun
protein, but not mRNA (Polack et al. 2006; Blau et al. 2012). Given that cJun is heavily
implicated in the oncogenesis of cancers, including hepatocarcinomas and glioblastomas,
the dramatic increase resulting from an anticancer drug is worthy of further investigation.
Particularly since cJun is highly necessary for liver formation during embryonic
development. Here we have shown that increased cJun does appear to increase OCT4A
protein in some instances following low-dose treatments with nocodazole.
Immunocytochemistry showed a striking increase in overall OCT4A expression as well
as areas of co-localization with cJun in the nuclei, further supporting our conclusion that
increased cJun expression increases OCT4A, but not the overall levels of OCT4 in the
cell. It is possible that there is a complimentary decrease in the other OCT4 isoforms
which prevents the overall levels from changing. Alternatively, it is possible that the
Oct4 all antibody is also identifying phosphorylated versions of OCT4. Each of these
possibilities warrant further investigation.
Unfortunately, we were not able to characterize the effect of nocodazole on
differentiation as nocodazole-treated cells were unable to form proper embryoid bodies
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under standard low-adherent conditions. Nocodazole causes the de-polymerization of
microtubules, which could affect the formation of cell-cell adhesions. These adhesions
are extremely important in determining germ layer formation and organization. As
gastrulation occurs, the cells that become the endoderm must undergo an epithelial to
mesenchymal transition (EMT) as they travel from the primitive streak to the underlying
hypoblast, where they will incorporate themselves. Upon cJun induction, cells begin to
rapidly upregulate genes involved in this EMT (Liu et al. 2015), which is consistent with
the established role of cJun in migration and invasion during the onset of both cancer
(Polak et al. 2006; Blau et al. 2012) and development (Veluscek et al. 2016). One
mechanism by which cJun contributes to this is direct binding of the Fn1 (Fibronectin)
locus, as epiblast-derived stem cells exit pluripotency, which results in subsequent altered
expression of the adhesion molecule N-cadherin (Veluscek et al. 2016). Together, this
could further implicate cJun, in part, as a key regulatory component during gastrulation.
Furthermore, it is possible that the cells undergo apoptosis prior to forming aggregates
due to a known role for cJun in cell death.

Conclusions
cJun is required for many cellular processes including proliferation and is implicated in a
variety of cancers. Here we have established a link between Oct4, the classic potency
marker, and cJun through which cell fate can be regulated. When the WT-cJun construct
is overexpressed, OCT4A is also increasingly expressed, but the overall levels of OCT4
in the cells do not seem to be affected. Considering that as little as a two-fold change in
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Oct4 transcriptional activity can alter cell fate toward mesoderm and endoderm or
trophoblast, it is possible that cJun regulation is an initial step in lineage commitment.
Upon transfection with cJun, increased OCT4 expression and differentiation into
embryoid bodies, there is a detectable increase in GATA4 protein. Based on previous
literature, GATA4 is required for specification of cardiac mesoderm as well as the
formation of liver buds from the foregut endoderm (Rossi et al. 2001). cJun is a
necessary component of this lineage commitment because cJun-/- embryos display
cardiac deformations and die by mid- to late-gestation (Eferl et al. 1999). Considering
the increase in cardiomyocyte activity when cells are transfected with cJun, it is
imperative that the link between cJun, Oct4 and cardiac fate be further explored.
Additionally, these data provide an interesting model which implicates cJun as a
regulator of Oct4 in a developmental context. Given the known role of cJun in
hepatogenesis and hepatocyte maintenance (Eferl et al. 1999), as well as the positive
feedback loop Oct4 initiates with cJun in hepatocarcinomas (Kuo et al. 2016), it would be
interesting to compare the diseased state with this developmental model.
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APPENDIX A

Optimization of Luciferase Assays

A

B

No Treatment

Sample
NT
NT
NT
egfp+Oct4
egfp+Oct4
egfp+Oct4
cJun + Oct4
cJun + Oct4
cJun + Oct4
Beta + Oct4
Beta + Oct4
Beta + Oct4
Top only
Top + Beta

Oct4 + eF1-GFP

Luciferase
Luc- Avg NT
71.21
57.95
64.7
32816.31
32751.69
43963.83
43899.21
24248.69
24184.07
21011.83
20947.21
24780.26
24715.64
19110
19045.38
65667.5
65602.88
65595.37
65530.75
61385.89
61321.27
11750.95
11686.33
17861746 17861681.38

Oct4 + cJun

Renilla
Renilla-Avg NT
62.89
60.12
50.48
23468.16
23410.33
56158.84
56101.01
30539.9
30482.07
9416.98
9359.15
13506.19
13448.36
18101.77
18043.94
13250.02
13192.19
15643.98
15586.15
7043.16
6985.33
745805.73
745747.9
760479.82
760421.99

F/R Ratio

1.399027267
0.782503024
0.793386735
2.238153037
1.837818143
1.055500074
4.972857425
4.204421875
8.778578822
0.015670617
23.48916998

Oct4 + Beta-catenin

Avg F/R Ratio

Fold Change

0.991639009

1

1.710490418

1.724912395

5.985286041

6.0357509
1498.930732

Supplemental Figure 1. Transfection Efficiency with New Oct4 Clone that
Encompasses Complete Promoter Sequence (-3066- +1)
A. Phase contrast images taken at 200X total magnification show 293T cells have been
successfully transfected with the various GFP-cJun plasmids as shown by positive GFP
signal. B. Subsequent luciferase assay data is shown as raw readouts from the
SpectraMaxL5. When first normalized firefly to Renilla signal and then to eF1-GFP
signal, both cJun and Beta-catenin alone appear to activate the Oct4 reporter by 1.7 and
6.0-fold change respectively.
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A

No Treatment

B

Sample

Luciferase

TOP FLASH +Beta-Catenin
Luc-Avg. NT

Renilla

Renilla-Avg. NT

NT

52.411538

76.88097

NT

51.447225

76.6398

NT

53.255311

87.24733

TOP FLASH
F/R Ratio

TOP

46587.90608

46535.53473

321203.5

321123.244

0.144914875

TOP

46601.05012

46548.67876

236737.4

236657.144

0.196692472

TOP

49612.64122

49560.26987

293445.8

293365.544

0.168936915

TOP + Beta

10718253

10718200.63

72760.63389

72680.37786

147.4703482

TOP + Beta

9553551.4

9553499.029

95580.6484

95500.39237

100.036228

TOP + Beta

10431421.2

10431368.83

715164.16

715083.904

14.5876152

Avg F/R

Fold Change

0.170181

87.36473
513.362329

Supplemental Figure 2. Positive Control Plasmid Transfection Efficiency
A. Phase contrast with fluorescent FITC filter identify GFP positive cells, which have
been successfully transfect with the TOP FLASH plasmid +/- Beta-catenin with a
pcDNA-GFP plasmid. B. Data table demonstrating raw values and the preliminary
calculations done to find the F/R ratio in relative light units (RLU) and ultimately the fold
change in TOP FLASH activation, which is approximately 513-fold change greater when
Beta-catenin is added. Based on this result, we moved forward using TOP FLASH with
Beta-catenin as a positive control for all subsequent transfections.

mESC

293T
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mESC Data

293T Data

No Treatment

TOP FLASH

TOP FLASH + Beta-Catenin

Sample
Luciferase Data
Luc-Avg NT
Renilla Data
Renilla- Avg NT
F/R Ratio
Avg F/R Ratio Fold change
NT
72.903182
75.675582
NT
72.541565
57.835796
NT
72.541565
57.112562
NT
70.251322
62.65736
TOP
20410.59723
20338.53782
6080.606901
6017.286576
3.380018147
TOP
19908.22377
19836.16436
2394.268346
2330.948021
8.509912781
TOP
28537.60735
28537.60735
15810.47111
15747.15079
1.812239416
TOP
24613.64481
24541.58541
8450.793697
8387.473372
2.925980724 2.706079429
TOP + BETA
17292592.41
17292520.35
29812.86952
29749.5492
581.2699963
TOP + BETA
17368849.88
17368777.82
22383.70305
22320.38273
778.1577062
TOP + BETA
17155446.74
17155374.68
17074.26093
17010.94061
1008.490658
TOP + BETA
18665461.62
18665389.56
16970.09992
16906.7796
1104.018034 963.5554659 356.0706517
Sample
Luciferase Data
Luc- Avg NT
Renilla Data
Renilla- Avg NT
F/R Ratio
Avg F/R Ratio Fold Change
NT
107.738986
63.621672
NT
125.337701
55.183937
NT
111.596239
63.380594
NT
82.66685
67.478923
TOP
18105.26709
17998.43214
310.365445
247.9491635
77.40591001
TOP
16201.91537
16095.08042
294.93641
232.5201285
69.22015967
TOP
17959.87441
17853.03947
415.4758
353.0595185
50.5666567
TOP
16953.4631
16846.62816
412.100696
349.6844145
48.1766629 61.34234732
TOP + BETA
104591.9666
104485.1317
1539.993809
1477.577528
70.7138067
TOP + BETA
111204.8622
111098.0273
3026.751377
2964.335096
37.47822823
TOP + BETA
111360.3862
111253.5513
2739.379204
2676.962923
41.55961607
TOP + BETA
109978.8963
109872.0613
568.561006
506.1447245
217.0763736 49.917217 0.813748074

Supplemental Figure 3. J1 mESCs Are Not Efficiently Transfected Compared to
293T
A. Phase contrast images (total magnification of 200X) show varied degrees of
transfection efficiency, with the 293T cells overall more successful based of GFP signal.
B. Luciferase assay data shows that 293T cells are able to show a fold change with the
positive control TOPFLASH plasmid greater than 300, while mESC show a decrease in
plasmid activity. Based on these results we concluded that efficiency was too low in
mESC to successfully carry out luciferase assays.
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293T
eF1-GFP

cJun

J1 mESC
L4042A

eF1-GFP

α cJun

α cJun

α GAPDH

α GAPDH

cJun

L4042A

Supplemental Figure 4. Expression of cJun Construct can be Detected by Western
Blot
293T (left) and J1 mES cells (right) were transiently transfected with the empty GFP
vector, WT- cJun or the L4042A mutant and harvested for protein. Western blots were
run using an anti- cJun antibody, and GAPDH as a loading control. Because efficiency
was too low for Luciferase Assays, it was imperative to confirm the product of the cJun
plasmids by western blot. Based on the above results, the cJun product from the plasmid
was strongly detected in J1 mESCs, albeit at lower levels than 293Ts.
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Analysis of Embryoid Body Formation and Germ Layer Expression

Day 0

Day 1

Day 2

Day 3

Day 3+4

Day 3+6

Supplemental Figure 5. Differentiation of mESC into Embryoid Bodies
Phase contrast images of J1 mES cells as they were differentiated from pluripotent
colonies (Day 0 and Day 1) toEBs (Day 3+4 and Day 3+6). Cells were seeded at 30,000
cells/cm2 and grown to 40% confluency. One million cells were lifted and plated to 0.1%
gelatin for 48 hours (Day 2 and Day 3). Following gelatin, cels were lifted and
maintained in ultra-low-adherent dishes for either four (Day 3+4) or six (Day 3+6) days
prior to harvest for further analysis.
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eF1-GFP

cJun

L4042A

Day 6

Day 4

No
Treatment

Supplemental Figure 6. GFP Plasmid Expression is Still Detected 4 and 6 Days After
Low Adherent Culture
Embryoid bodies were imaged at 10X for GFP expression. eF1-GFP was still easily
detectable in EBs following low adherent conditions, likely due to its cytoplasmic
location. cJun and L4042A were not as visible due to their nuclear localization, however
some faintly GFP positive cells were still detected. cJun appeared to have more GFP
positive areas than L4042A, however efficiency with L4042A was lower initially.
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Day 4 EB

A

Day 6 EB

No
No
Treatment eF1-GFP cJun L4042A Treatment eF1-GFP cJun L4042A

C

Average Day 4 EB Densitometry
Values Normalized to GAPDH

αBrachyury
GATA
4

αGATA4

BRY Sox1

αSox1
αGAPDH

Day 4 EB

B

Mean
Standard Error
Mean
Standard Error
Mean
Standard Error

D

αBrachyury

cJun
0.050
0.032
0.044
0.016
0.139
0.044

L4042A
0.036
0.013
0.037
0.005
0.147
0.057

Average Day 6 EB Densitometry
Values Normalized to GAPDH

BRY SOX1

GATA
4

αGATA4

αGAPDH

eF1-GFP
0.048
0.011
0.076
0.035
0.123
0.035

Day 6 EB

No
No
Treatment eF1-GFP cJun L4042A Treatment eF1-GFP cJun L4042A

αSox1

NT
0.085
0.048
0.070
0.054
0.135
0.023

Mean
Standard Error
Mean
Standard Error
Mean
Standard Error

NT
0.177
0.137
0.035
0.010
0.139
0.033

ef1gfp
0.161
0.124
0.050
0.009
0.161
0.070

cJun
0.257
0.150
0.068
0.036
0.172
0.073

L4042A
0.163
0.097
0.053
0.008
0.157
0.055

Supplemental Figure 7. Replicated Western Blots Show an Increase in GATA4
when cJun is Over-Expressed
A-B. mESCs were transfected and differentiated, as previously done. While experimental
variables were kept constant, these replicates demonstrate variation in Sox1 and
Brachyury expression. GATA4 expression patterns also showed minor variations.
However, EBs grown in culture for 6 days after transfection with cJun do appear to
maintain the trend of elevated GATA4 expression compared to the other samples. C-D.
Tables with the mean germ layer expression, normalized to GAPDH and the standard
error.
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Chemical Modulation of cJun/JNK Signaling

αOCT4A
αOCT4
αGAPDH
Supplemental Figure 8. OCT4A Expression is Not Significantly Altered After Two
Hour Treatment
J1 mESCs were harvested two hours post-treatment with DMSO, a JNK inhibitor
(SP600125), a JNK activator (Anisomycin) or a cytoskeletal disruptor (Nocodazole). Not
in agreement with our expected results, OCT4A remained seemingly unchanged across
treatments. Because of this, we included a four-hour time point for subsequent drug
treatments.
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Supplemental Figure 9. There is Variation in Potency Marker Expression Under
Drug Modulation
While somewhat similar to the data in main figure 7, this replicate demonstrates variation
in the expression of potency markers SOX2, NANOG and OCT4A. OCT4 all, however
appears to remain relatively constant.
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APPENDIX B

Antibody Information
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Supplemental Table 1. Antibodies Used for Immunoblot and Immunocytochemistry
Target
Western Blot Antibodies
cJun
Phospho-cJun S63
Phospho-cJun S73
JNK I/II/III
Phospho-JNK
OCT4
Oct4A
SOX2
NANOG
eGFP
GATA4
BRACHYURY
SOX1
GADPH
(Secondary) Goat antiRabbit IgG (H+L)
Immunocytochemistry
Antibodies
cJun
OCT4
OCT4A
(Secondary) Texas Red
Rabbit IgG
(Secondary) Texas Red
Mouse IgG
(Secondary) Goat anti
Guinea Pig IgG H&L
(FITC)

Manufacturer &Catalog
Number

Working Dilution

Abcam #ab32137
Abcam #ab32385
Cell Signaling #3270s
Abcam
Abcam #ab124956
Abcam #ab19857
Cell Signaling #2840s
Cell Signaling #4195
Santa Cruz Biotech
#sc293121
Clonetech #632381
Abcam #ab84593
Abcam #ab20680
Abcam #ab87775
Cell Signaling #97166
Abcam #ab6721

1/1000
1/1000
1/1000
1/1000
1/1000
1/1000
1/1000
1/500
1/500

Abcam #ab32137
Abcam #ab19857
Cell Signaling #2840s
Life Technologies #A-6399

1/1000
1/1000
1/1000
5g/mL

Life Technologies #T6390

5g /mL

Abcam #ab69041

1/200

1/1000
1/500
1/500
1/250
1/1000
1/2000

